Managing treatment-related adverse events associated with EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer

Non-small-cell lung cancer (NSCLC) has the highest prevalence of all types of lung cancer, which is the second most common cancer and the leading cause of cancer-related mortality in Canada. The need for more effective and less toxic treatment options for NSCLC has led to the development of agents targeting the epidermal growth factor receptor (EGFR)-mediated signalling pathway, such as EGFR tyrosine kinase inhibitors (EGFR-TKIS). Although EGFR-TKIS are less toxic than traditional anti-neoplastic agents, they are commonly associated with acneiform-like rash and diarrhea. This review summarizes the clinical presentation and causes of EGFR-TKI-induced rash and diarrhea, and presents strategies for effective assessment, monitoring, and treatment of these adverse effects. Strategies to improve the management of EGFR-TKI-related adverse events should improve clinical outcomes, compliance, and quality of life in patients with advanced NSCLC.